A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study.
To assess the possible benefit of hormone replacement therapy (HRT) in the secondary prevention of ischaemic heart disease. A prospective randomised trial of transdermal HRT in women with definite ischaemic heart disease. A regional cardiac unit. Postmenopausal women with angiographically proven ischaemic heart disease. A total of 255 postmenopausal women with angiographically proven ischaemic heart disease were recruited and randomised; 134 were treated with transdermal HRT and 121 acted as controls. The women were seen at six monthly intervals. The primary end points, which were determined by a blinded assessor, were admission to hospital with unstable angina, proven myocardial infarction or cardiac death. A total of 53 (40%) patients withdrew from the HRT group and eight (7%) from the control group. The mean duration of follow up was 30.8 months. Admission to hospital with unstable angina, proven myocardial infarction or cardiac death. During follow up, there were 53 primary end-point events in the HRT group and 37 in the control group. Using an intention-to-treat analysis, the primary end-point event rate was 15.4 events per 100 patient years for the HRT group compared with 11.9 for the control group (event rate ratio 1.29 (95% CI 0.84-1.95, P = 0.24)). Using a per-protocol analysis, there was an event rate ratio of 1.49 (0.93-2.36, P = 0.11) for the HRT arm compared with the control arm. Particularly during the first two years of follow up, the HRT group had a higher, but not statistically significant, event rate than the control group. Our findings suggest that transdermal HRT should not be commenced for the purpose of secondary prevention in postmenopausal women with angiographically proven ischaemic heart disease.